Podcasts - 10 Oct `24 From DNA to AI: Progress and Hope in Vitiligo Research (Ep. 2)

Podcast

Discover the future of vitiligo treatment in our latest episode, where we spotlight cutting-edge therapies transforming care for this complex condition. From Incyte's Opzelura, the first FDA-approved drug for vitiligo, to Temprian Therapeutics’ DNA-based treatments and Clinuvel’s synthetic hormones for full-body repigmentation, we explore the innovations redefining the field.

Learn how industry leaders like Amgen and Pfizer are moving beyond cosmetic solutions with advanced targeted therapies. Amgen’s AMG-714 blocks interleukin-15 to protect melanocytes, while Pfizer’s oral drug Litfulo targets immune pathways for systemic repigmentation. We also delve into the role of AI in diagnostics, featuring Skinopathy’s groundbreaking collaborations.

This episode captures the excitement and momentum driving vitiligo research and development. With these advancements, the future looks promising for more effective, accessible, and personalized treatments. Join us for an insightful dive into the breakthroughs offering hope to millions.



FAQOther Questions

  • How to get insurance coverage for vitiligo treatments?

    Getting insurance coverage for vitiligo treatments can be challenging, but there are several steps you can take to improve your chances For a more in-depth look, check out our ...

  • Red Wine and Vitiligo

    Recent research has revealed intriguing findings about the potential protective effects of red wine against vitiligo, using a genetic approach to study health outcomes. Red Win...

  • Vitiligo and hearing loss: any connection?

    Vitiligo is primarily recognized for causing skin discoloration, but it can also impact melanocytes in unexpected areas, such as the inner ear. This raises questions about wheth...